PEPTIDE BASED TARGETED RADIONUCLIDE THERAPIES; SCIENCE BEHIND THE SUCCESS.
The radionuclide therapies for solid and liquid malignancies are emerging field nowadays. The targeted radionuclide therapies have been in use since 1945. In the past 20 years, due to advancement in the nanotechnology and targeting cell receptors; radionuclide therapies have emerged as a subspecialty in nuclear medicine. Through this article, we would like to briefly describe the evolution of peptide-based radionuclide therapies, with a little emphasis on their clinical applications.
Key words: Peptide-based radiopharmaceuticals, radionuclide therapy, somatostatin-receptor-positive neuroendocrine tumour
Flux G, Bardies M, Monsieurs M, et al. The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. Z Med Phys 2006;16:47-59.
Dale R, Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm 2005;20:47-51.
Larson SM, Krenning EP. A pragmatic perspective on molecular targeted radionuclide therapy. J Nucl Med 2005;46 Suppl 1:1S-3S.
Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 2003;52:281-96.
Oberg K. Pancreatic endocrine tumors. Semin Oncol 2010;37:594-618.
Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-59.
The NCCN Clinical Practice Guidelines in Oncology. Neuroendocrine Tumours. Version 1.2016. United States: National Comprehensive Cancer Network, Inc.; 2011.
Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: A clinical review. Oncologist 2005;10:123-31.
Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005;54 Suppl 4:iv1-16.
Modlin IM, Latich I, Kidd M, et al. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 2006;4:526 47.
Weckbecker G, Lewis I, Albert R, et al. Opportunities in somatostatin research: Biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2003;2:999-1017.
Maecke HR, Reubi JC. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J Nucl Med 2011;52:841-4.
Rindi G. The ENETS guidelines: The new TNM classi cation system. Tumori 2010;96:806-9.
ModlinIM,ObergK,ChungDC,etal.Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72.
SundinA,VulliermeMP,KaltsasG,etal.ENETSconsensus guidelines for the standards of care in neuroendocrine tumors: Radiological examinations. Neuroendocrinology 2009;90:167-83.
Bombardieri E, Ambrosini V, Aktolun C, et al. Oncology Committee of the EANM. 111In-pentetreotide scintigraphy: Procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37:1441-8.
Virgolini I, Ambrosini V, Bomanji JB, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA- conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA- NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging J Cancer Allied Spec 2016;2(4):2 2010;37:2004-10.
Binderup T, Knigge U, Loft A, et al. 18F- uorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010;16:978-85.
Kerström G, Hellman P, Hessman O. Midgut carcinoid tumours: Surgical treatment and prognosis. Best Pract Res Clin Gastroenterol 2005;19:717-28.
Plöckinger U, Couvelard A, Falconi M, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: Well-differentiated tumour/ carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology 2008;87:20-30.
Ramage JK, Goretzki PE, Manfredi R, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: Well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology 2008;87:31-9.
De Jong M, Bakker WH, Breeman WA, et al. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor targeted scintigraphy and radionuclide therapy. Int J Cancer 1998;75:406-11.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.